RT Journal Article
SR Electronic
T1 mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.12.23.424138
DO 10.1101/2020.12.23.424138
A1 Susanne Rauch
A1 Karen Gooch
A1 Yper Hall
A1 Francisco J. Salguero
A1 Mike J. Dennis
A1 Fergus V. Gleeson
A1 Debbie Harris
A1 Catherine Ho
A1 Holly E. Humphries
A1 Stephanie Longet
A1 Didier Ngabo
A1 Jemma Paterson
A1 Emma L. Rayner
A1 Kathryn A. Ryan
A1 Sally Sharpe
A1 Robert J. Watson
A1 Stefan O. Mueller
A1 Benjamin Petsch
A1 Miles W. Carroll
YR 2020
UL http://biorxiv.org/content/early/2020/12/23/2020.12.23.424138.abstract
AB The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic necessitates the fast development of vaccines to meet a worldwide need. mRNA-based vaccines are the most promising technology for rapid and safe SARS-CoV-2 vaccine development and production. We have designed CVnCoV, a lipid-nanoparticle (LNP) encapsulated, sequence optimised mRNA-based SARS-CoV-2 vaccine that encodes for full length, pre-fusion stabilised Spike protein. Unlike other mRNA-based approaches, CVnCoV exclusively consists of non-chemically modified nucleotides and can be applied at comparatively low doses. Here we demonstrate that CVnCoV induces robust humoral and cellular responses in non-human primates (NHPs). Animals vaccinated with 8 μg of CVnCoV were protected from challenge infection with SARS-CoV-2. Comprehensive analyses of pathological changes in challenged animals via lung histopathology and Computed Tomography (CT) scans gave no indication of enhanced disease upon CVnCoV vaccination. These results demonstrate safety, immunogenicity, and protective efficacy of CVnCoV in NHPs that extend our previously published preclinical data and provide strong support for further clinical testing in ongoing phase 2b/3 efficacy studies.Competing Interest StatementS.R., B.P., and S.O.M. are employees of CureVac AG, Tuebingen Germany, a publically listed company developing RNA-based vaccines and immunotherapeutics. All authors may hold shares or stock options in the company. S.R. and B.P. inventors on several patents on mRNA vaccination and use thereof.